Gold, Neither you nor I know why Mr.Frost left Abbott. I would assume many people come and go to and from Abbott.
Do you have any documentation showing what happened? You keep bringing this up as fact?
I really don't care what happened to Mr. Frost. All I did was show you In print:
Preliminary studies indicate that RECAF may provide good clinical sensitivity and specificity as a tumor marker," said William Brown, Ph.D., vice president, Diagnostic Assays and Systems Development, Abbott. "Abbott's goal is to further develop this technology, incorporating it into future tests on our ARCHITECT® system, for use in cancer diagnosis and monitoring."
BioCurex and Abbott Jointly Present RECAF Results at International Cancer Congress
